2014; Zeng et al. 2014; Wang et al. 2019). The comprehensive analysis of network pharmacology and sequencing in the early stage found that PI3K signalling pathway was involved in the therapeutic effect of SSJZF on NAFLD (Figure 7(A)). Here, in order to confirm whether SSJZF regulates PI3K/Akt signalling pathway in liver tissue of NAFLD rats, western blot analyses were performed to verify the PI3K/Akt signalling pathway activation in NAFLD rats with or without SSJZF treatment (Figure 7(B,C)). The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.